Bionano Genomics ((BNGO)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bionano Genomics’ latest earnings call painted a cautiously optimistic picture, balancing near‑term revenue softness with clear structural improvements. Management emphasized sharp margin gains, deep cost cuts, reimbursement wins, and growing scientific adoption, while also acknowledging modest top-line declines, supply bottlenecks, customer concentration, and tight liquidity.
Full-Year Revenue Trends and 2026 Top-Line Setup
Bionano reported 2025 revenue of $28.5 million, down 7% year over year from $30.8 million, signaling that the business is still working through growth challenges. Management set 2026 revenue guidance at $30 million to $33 million, implying a return to growth of roughly 5% to 16% off the lower 2025 base.
Non-GAAP Gross Margin Expansion Signals Healthier Economics
Non-GAAP gross margin for 2025 improved to 47%, up sharply from 35% in 2024, a 1,200 basis point jump that materially improves unit economics. In the fourth quarter, non-GAAP gross margin came in at 43%, slightly above the 42% level a year earlier despite revenue pressure.
Cost Structure Overhaul and Operating Expense Discipline
Non-GAAP operating expenses dropped to $36.6 million in 2025, down 47% from $68.9 million in 2024, highlighting a significant reset of the cost base. Since the second quarter of 2023, Bionano has removed about $100 million in annualized non-GAAP operating expense and cut headcount by more than 300 employees.
Strategic Shift Toward Higher-Quality Consumables and Software
Consumables and software revenue rose 7% year over year to $20.4 million in 2025 and grew from 62% to 71% of total revenue, showing progress toward more recurring, higher-margin business. This mix shift is central to management’s strategy to build a more predictable revenue base less dependent on one-time system sales.
Installed Base Growth Outperforms and Expands Customer Footprint
The company installed 32 optical genome mapping systems in 2025, above its initial guidance of 15 to 20 systems, pointing to solid demand despite budget pressures in key markets. By year-end, Bionano had 387 systems deployed across 321 customers, building a broader platform for consumables pull-through.
Routine-Use Customers Anchor Consumables Monetization
About 130 routine-use customers, representing roughly 40% of the customer base and 45% of systems, generated around 83% of OGM consumables revenue in 2025. These high-value users averaged about $89,000 in consumables revenue each, with 60 validated routine sites averaging roughly $131,000 and accounting for over half of total consumables revenue.
Scientific Momentum Underscores Growing Optical Genome Mapping Adoption
Bionano recorded 136 new peer-reviewed OGM publications in 2025, up 25% year over year, bringing total publications to about 450. Clinical research genomes added roughly 1,190 during the year for a cumulative nearly 12,700, reflecting a roughly 30% compound annual growth rate since 2021.
Reimbursement Milestones Strengthen Commercial Foundation
The company secured a second Category I CPT code for constitutional disorders with a payment level above $1,200, broadening reimbursed indications. In hematologic malignancies, the CPT payment rate increased 47% to more than $1,800 in the 2026 clinical fee schedule, materially improving the economic case for adoption.
Product and Throughput Enhancements Boost System Productivity
Bionano launched VIA 7.2 to extend automated workflow capabilities into constitutional disorders and updated Solve to version 3.8.3 with a broader control database. A Stratus compute upgrade using advanced GPUs doubled weekly cancer sample throughput without new hardware, while IONIQ expansion supports high-purity DNA and RNA isolation at scale.
Scaling Evidence from Community Engagement and Partnerships
The 2026 Bionano Symposium drew more than 1,250 registrants from 73 countries, signaling global interest in OGM. Presentations highlighted real-world scaling, including Radboud ramping toward 3,000 samples per year and Labcorp demonstrating Stratus capacity for up to 10,000 cancer samples annually.
Balance Sheet Position and Debt Simplification Milestone
Bionano ended 2025 with $29.6 million in cash, cash equivalents, and available-for-sale securities, including $10.3 million that is restricted, a modest buffer for its operating scale. Management expects cash runway into 2027 and plans to fully retire its senior secured convertible debt in May 2026, simplifying the capital structure.
Top-Line Headwinds from Full-Year and Q4 Revenue Declines
Despite structural improvements, full-year revenue fell 7% to $28.5 million and fourth-quarter revenue dipped 3% to $8.0 million versus the prior year. These declines highlight that better margins and reimbursements have not yet translated into sustained top-line acceleration.
Supply Constraints Weigh on Q4 Consumables Volumes
In the fourth quarter, Bionano sold 7,554 nanochannel array flow cells, down 6% year over year, with full-year volumes essentially flat at 30,171. Management cited late-quarter silicon wafer delays at a manufacturing partner, which limited flow-cell supply, muted consumables growth, and created backlog expected to convert in 2026.
Software Revenue Timing Creates Q4 Volatility
Fourth-quarter consumables and software revenue slipped 1% to $4.8 million, driven largely by a 22% decline in software revenue. Management attributed the drop to a few large orders that were pulled forward into earlier quarters, underscoring near-term timing noise even as the mix shifts toward these higher-quality streams.
Customer Concentration Presents Ongoing Revenue Risk
With roughly 40% of customers classified as routine-use yet generating about 83% of consumables revenue, Bionano faces meaningful concentration risk. Any slowdown in utilization or funding at this subset of sites could disproportionately impact results, making diversification of the user base a key strategic priority.
Liquidity Constraints Heighten Execution Imperative
Year-end liquidity of $29.6 million, including restricted cash, is relatively modest, especially given the company’s global footprint and R&D needs. While management cites a runway into 2027 and upcoming debt retirement, investors will watch cash burn and capital access closely as the growth plan plays out.
Guidance Hinges on Execution Across Customers and Operations
Bionano’s 2026 revenue guidance of $30 million to $33 million and first-quarter guidance of $6.5 million to $6.7 million assume seasonal improvement and consumables volumes growing alongside revenue. Hitting these targets will depend on bringing more customers into routine use, resolving supply constraints, and fully capturing reimbursement tailwinds while maintaining tight cost discipline.
The call sketched a story of a company that has materially improved its underlying economics but still must prove it can convert those gains into consistent revenue growth. For investors, Bionano now looks more structurally sound, yet its path to scale remains execution-heavy, making 2026 a pivotal year to validate the model and de-risk the story.